Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance
International Journal of Molecular Sciences · 22.02.2023 · 24 (5) · 4354
DOI: 10.3390/ijms24054354 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.02.2023. Verfasst von Amaia Ezkurdia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Metabolic Syndrome, Insulin Resistance, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 148-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de ciencia e innovación, Spain, Spanish Ministry of Science and Innovation Competitiveness.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the main type of dementia and is a disease with a profound socioeconomic burden due to the lack of effective treatment. In addition to genetics and environmental factors, AD is highly associated with metabolic syndrome, defined as the combination of hypertension, hyperlipidemia, obesity and type 2 diabetes mellitus (T2DM). Among these risk factors, the connection between AD and T2DM has been deeply studied. It has been suggested that the mechanism linking both conditions is insulin resistance. Insulin is an important hormone that regulates not only peripheral energy homeostasis but also brain functions, such as cognition. Insulin desensitization, therefore, could impact normal brain function increasing the risk of developing neurodegenerative disorders in later life. Paradoxically, it has been demonstrated that decreased neuronal insulin signalling can also have a protective role in aging and protein-aggregation-associated diseases, as is the case in AD. This controversy is fed by studies focused on neuronal insulin signalling. However, the role of insulin action on other brain cell types, such as astrocytes, is still unexplored. Therefore, it is worthwhile exploring the involvement of the astrocytic insulin receptor in cognition, as well as in the onset and/or development of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain.
- IdISNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
ORCID-Profile: Amaia Ezkurdia, María J Ramírez, Maite Solas
Förderung
- Ministerio de ciencia e innovación, Spain
- Spanish Ministry of Science and Innovation Competitiveness
Zitieren
APA
Ezkurdia, A., Ramírez, M. J., & Solas, M. (2023). Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance. International Journal of Molecular Sciences, 24(5), 4354. https://doi.org/10.3390/ijms24054354
Vancouver
Ezkurdia A, Ramírez MJ, Solas M. Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance. International Journal of Molecular Sciences. 2023;24(5):4354. doi:10.3390/ijms24054354
BibTeX
@article{Ezkurdia2023,
author = {Ezkurdia, Amaia and Ramírez, María J and Solas, Maite},
title = {Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {5},
pages = {4354},
doi = {10.3390/ijms24054354}
}
EUVIMED